Annual CFF
$388.94 M
+$266.98 M+218.90%
31 December 2023
Summary:
Crinetics Pharmaceuticals annual cash flow from financing activities is currently $388.94 million, with the most recent change of +$266.98 million (+218.90%) on 31 December 2023. During the last 3 years, it has risen by +$136.26 million (+53.93%). CRNX annual CFF is now at all-time high.CRNX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$57.33 M
+$51.83 M+943.07%
30 September 2024
Summary:
Crinetics Pharmaceuticals quarterly cash flow from financing activities is currently $57.33 million, with the most recent change of +$51.83 million (+943.07%) on 30 September 2024. Over the past year, it has increased by +$19.40 million (+51.16%). CRNX quarterly CFF is now -85.43% below its all-time high of $393.57 million, reached on 31 March 2024.CRNX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$494.32 M
-$280.55 M-36.21%
30 September 2024
Summary:
Crinetics Pharmaceuticals TTM cash flow from financing activities is currently $494.32 million, with the most recent change of -$280.55 million (-36.21%) on 30 September 2024. Over the past year, it has increased by +$105.38 million (+27.09%). CRNX TTM CFF is now -36.79% below its all-time high of $782.03 million, reached on 31 March 2024.CRNX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRNX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +51.2% | +27.1% |
| 3 y3 years | +53.9% | -65.0% | +95.6% |
| 5 y5 years | +10000.0% | +10000.0% | +10000.0% |
CRNX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +218.9% | -85.4% | >+9999.0% | -36.8% | +3348.8% |
| 5 y | 5 years | at high | >+9999.0% | -85.4% | >+9999.0% | -36.8% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -85.4% | >+9999.0% | -36.8% | >+9999.0% |
Crinetics Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $57.33 M(+943.1%) | $494.32 M(-36.2%) |
| June 2024 | - | $5.50 M(-98.6%) | $774.87 M(-0.9%) |
| Mar 2024 | - | $393.57 M(+937.8%) | $782.03 M(+101.1%) |
| Dec 2023 | $388.94 M(+218.9%) | $37.92 M(-88.8%) | $388.94 M(+10.8%) |
| Sept 2023 | - | $337.88 M(+2569.3%) | $351.13 M(+2349.8%) |
| June 2023 | - | $12.66 M(+2515.3%) | $14.33 M(-88.1%) |
| Mar 2023 | - | $484.00 K(+320.9%) | $120.67 M(-1.1%) |
| Dec 2022 | $121.96 M(-51.7%) | $115.00 K(-89.3%) | $121.96 M(-57.3%) |
| Sept 2022 | - | $1.08 M(-99.1%) | $285.70 M(-4.8%) |
| June 2022 | - | $118.99 M(+6584.9%) | $300.09 M(+18.0%) |
| Mar 2022 | - | $1.78 M(-98.9%) | $254.40 M(+0.7%) |
| Dec 2021 | $252.68 M(+120.5%) | $163.86 M(+959.7%) | $252.68 M(+184.2%) |
| Sept 2021 | - | $15.46 M(-78.9%) | $88.92 M(+21.3%) |
| June 2021 | - | $73.30 M(>+9900.0%) | $73.30 M(-32.2%) |
| Mar 2021 | - | $57.00 K(-41.2%) | $108.15 M(-5.6%) |
| Dec 2020 | $114.57 M | $97.00 K(-161.4%) | $114.57 M(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$158.00 K(-100.1%) | $114.49 M(-0.2%) |
| June 2020 | - | $108.15 M(+1568.5%) | $114.67 M(+1656.3%) |
| Mar 2020 | - | $6.48 M(>+9900.0%) | $6.53 M(+9644.8%) |
| Dec 2019 | $67.00 K(-100.0%) | $17.00 K(-22.7%) | $67.00 K(+13.6%) |
| Sept 2019 | - | $22.00 K(+175.0%) | $59.00 K(-99.9%) |
| June 2019 | - | $8000.00(-60.0%) | $107.23 M(+0.5%) |
| Mar 2019 | - | $20.00 K(+122.2%) | $106.71 M(-37.3%) |
| Dec 2018 | $170.20 M(+1339.6%) | $9000.00(-100.0%) | $170.20 M(-4.0%) |
| Sept 2018 | - | $107.19 M(<-9900.0%) | $177.26 M(+153.0%) |
| June 2018 | - | -$513.00 K(-100.8%) | $70.06 M(-6.9%) |
| Mar 2018 | - | $63.51 M(+798.2%) | $75.28 M(+536.8%) |
| Dec 2017 | $11.82 M(<-9900.0%) | $7.07 M(<-9900.0%) | $11.82 M(+148.8%) |
| Sept 2017 | - | -$10.00 K(-100.2%) | $4.75 M(-0.2%) |
| June 2017 | - | $4.71 M(+9137.3%) | $4.76 M(+9237.3%) |
| Mar 2017 | - | $51.00 K | $51.00 K |
| Dec 2016 | -$53.00 K | - | - |
FAQ
- What is Crinetics Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals quarterly CFF year-on-year change?
- What is Crinetics Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals TTM CFF year-on-year change?
What is Crinetics Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of CRNX is $388.94 M
What is the all time high annual CFF for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high annual cash flow from financing activities is $388.94 M
What is Crinetics Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of CRNX is $57.33 M
What is the all time high quarterly CFF for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high quarterly cash flow from financing activities is $393.57 M
What is Crinetics Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, CRNX quarterly cash flow from financing activities has changed by +$19.40 M (+51.16%)
What is Crinetics Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of CRNX is $494.32 M
What is the all time high TTM CFF for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high TTM cash flow from financing activities is $782.03 M
What is Crinetics Pharmaceuticals TTM CFF year-on-year change?
Over the past year, CRNX TTM cash flow from financing activities has changed by +$105.38 M (+27.09%)